French OTC Industry Warns Over-Regulation Is Threatening Its Future
Executive Summary
Plans to move ibuprofen, aspirin and paracetamol OTCs behind the counter in French pharmacies will harm the country's self-medication industry, which is already lagging behind its European neighbors, warns local association Afipa.
You may also be interested in...
French OTC Industry Frustrated By Regulatory Clampdown in 2019
Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.
France Orders On-Pack Warnings For Paracetamol Over Liver Damage Fears
Fears over misuse mean all paracetamol-containing products (also known as acetaminophen) sold in France will from next year be required to carry prominent on-pack warnings.
France Reverse-Switches Flurbiprofen Against Backdrop Of NSAID Concerns
France has unexpectedly reverse switched to prescription status flurbiprofen, the active ingredient in Reckitt's Strefen. The move comes shortly after the country's medicines agency warned of serious adverse events related to certain NSAIDs.